Skip to content
You are now leaving https://www.ionispharma.com to visit

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life- -Akcea prepared for launch following approval- CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ —  Ionis Pharmaceuticals, Inc.